Conclusions: “The time to sustained alleviation of all signs and symptoms of Covid-19 did not differ significantly between participants who received nirmatrelvi

Conclusions: “The time to sustained alleviation of all signs and symptoms of Covid-19 did not differ significantly between participants who received nirmatrelvir–ritonavir (Paxlovid) and those who received placebo" - This Pfizer funded study concluded in July 2022 and was publicly released last month. [0] [1] - Pfizer's press release in late 2021 reported 89% reduction in hospitalization or death compared to placebo. [2] - In December 2022, the US Government spent another $2 billion on Paxlovid bringing the total spent to 12.6 billion.[3] [0] https://www.nejm.org/doi/full/10.1056/NEJMoa2309003#tab-contributors https://www.nejm.org/doi/full/10.1056/NEJMoa2309003#tab-cont... [1] https://clinicaltrials.gov/study/NCT05011513 https://clinicaltrials.gov/study/NCT05011513 [2] https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate https://www.pfizer.com/news/press-release/press-release-deta... [3] https://www.reuters.com/world/us/us-pay-pfizer-nearly-2-bln-more-paxlovid-courses-2023-2022-12-13/ https://www.reuters.com/world/us/us-pay-pfizer-nearly-2-bln-...